Previous close | 17.76 |
Open | 18.24 |
Bid | 17.29 x 100 |
Ask | 17.43 x 200 |
Day's range | 17.16 - 18.24 |
52-week range | 10.38 - 20.67 |
Volume | |
Avg. volume | 128,013 |
Market cap | 911.566M |
Beta (5Y monthly) | 1.08 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.69 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 24.60 |
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter ended March 31, 2024, and highlighted recent corporate progress.
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced changes to its Board of Directors with the appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. as independent directors, and the resignation of Isan Chen, M.D. The changes are effective immediately.
Recent Financial Highlights Indicate Strong Cash Position and Advancements in Clinical Studies